Navigation Links
Lupus Foundation of Florida Applauds Support for Biosimilars Legislation
Date:4/3/2013

TALLAHASSEE, Fla., April 3, 2013 /PRNewswire-USNewswire/ -- The Lupus Foundation of Florida applauds the Health Policy committee of the Florida Senate for the passage of Senate Bill 732 out of committee.  The legislation will allow biologic medicines to be automatically substituted with interchangeable biosimilar medicines by pharmacists.  It would also ensure doctors are made aware of product substitution and ensure records of biosimilar substitution are kept for a reasonable amount of time.

"As a patient advocate, I overwhelmingly support this bill, which sets guidelines for safely introducing biosimilar drugs into the Florida pharmaceutical market," said Linda Reucher , Program Director of The Lupus Foundation of Florida. "Senator Grimsley's bill supports transparency of our healthcare system and provides the most vulnerable Floridians – the elderly and chronically ill – affordable access to these life-changing medications.  The bill will also ensure that doctors and their patients have the most accurate information available, which ensures the highest standard of medical care."

The Food and Drug Administration will likely approve biosimilars in the next year or two and they will soon be made available to patients.  Setting up a framework for patients to access biosimilars at pharmacy counters and ensuring the safe substitution and tracking of these highly complex products now – rather than down the road – makes sense.

As the name indicates biosimilars are similar, though not exact copies of their reference biologic product, and so even miniscule changes between a biologic and its biosimilar products might affect lupus patients and other patients taking biologic medicines.

There are approximately 1.5 million Americans with lupus and 90,000 in the state of Florida. When lupus fails to respond to traditional treatment methods, lupus patients may be prescribed biologics, particularly Rituxan and Benlysta. This is quite common in lupus nephritis which affects about half of all lupus patients.

About the Lupus Foundation of Florida
Since 1979, the Lupus Foundation of Florida has been serving Floridians affected by lupus. We are part of the Lupus Research Institute National Coalition whose funding of novel research brings the day closer when we can say, there is "Life without Lupus." Visit our website at www.lupusflorida.org.


'/>"/>
SOURCE Lupus Foundation of Florida
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease
2. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
3. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
6. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
7. Two Of The Nations Top Specialists In Lupus, Drs. Swamy Venuturupalli & Daniel Wallace, Join In Expanding Research On Auto-Immune Diseases
8. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
9. American Academy of Family Physicians Foundation Launches Cities for Life
10. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
11. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Ungarn, February 12, 2016 ... das sich auf den ungedeckten medizinischen Bedarf ... positive Ergebnisse seines klinischen Forschungsprogramms bekannt. Das ... beschäftigt, ergab Verbesserungen ihrer respiratorischen Funktionen und ... ltd , ein Medizintechnikunternehmen, das sich auf ...
(Date:2/11/2016)... , Feb. 11, 2016 ... Diagnostics in Personalized Medicine and Cancer Therapy. - ... High-Growth Diagnostic Testing Markets. - Key Diagnostic Testing ... - Molecular Diagnostics in Genetic Testing. - Molecular ... Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... Stem cells are primitive cells found in ... the capacity to differentiate into mature cell types Stem ... first mouse embryonic stem cells were derived from embryos ... the first culturing of embryonic stem cells from non-human ... until 2006 As a result of these discoveries, stem ...
Breaking Medicine Technology:
(Date:2/13/2016)... Canada (PRWEB) , ... February 13, 2016 , ... In ... foot forward. They’ll groom themselves to perfection, go out of their way to be ... date – just take a look at any online dating profile. , A ...
(Date:2/12/2016)... DC (PRWEB) , ... February ... ... Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop ... The partnership will recruit top students from U.S. universities who will draw ...
(Date:2/12/2016)... ... , ... As a former television executive, owner Tal Rabinowitz knows how stressful ... decompress, Rabinowitz found herself drawn to a casual meditation class while working at NBC ... implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, she ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Every winter, someone ... This winter the West Penn Burn Center, part of the Allegheny Health ... to bring you the “Space Heaters Need Space” campaign. , “Space ...
(Date:2/12/2016)... ... , ... Erlanger Agency has announced a new partnership in its ongoing community ... on the fight against breast cancer, fundraising for a local woman named Carmen, who ... Carmen is a loving single mother of two boys who also serves as caregiver ...
Breaking Medicine News(10 mins):